Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8804762 | 0.82 | LMNA (0.41) | CA12CA1CA2CA9POLB | |
| SCHEMBL16513211 | 0.81 | POLB (0.44) | POLBKDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL28486944 | 0.79 | CYP3A4 (0.73) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL16800062 | 0.77 | POLB (0.62) | POLBKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL8583084 | 0.70 | TDP1 (0.40) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL5213994 | 0.68 | POLB (0.42) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL3586790 | 0.68 | KMT2A (0.51) | CA12CA1CA2CA9POLB | |
| SCHEMBL7027649 | 0.68 | CA12 (0.49) | CA12CA1CA2CA9POLB | |
| SCHEMBL4801866 | 0.67 | POLB (0.45) | POLBALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL8580977 | 0.67 | POLB (0.49) | POLBKDM4EALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HOFFMAN-LA ROCHE INC. | 2014-11-27 | — | — | US | disclosed |
| US-8829029-B2 | Dual modulators of 5HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-0498331-B1 | N-(aryloxyalkyl)heteroaryl-8-azabicyclo(3.2.1)octanes, intermediates and a process for the preparation thereof and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1996-05-22 | — | — | EP | disclosed |
| US-5340936-A | Antipsychotic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-23 | — | — | US | disclosed |
| US-5334599-A | Heteroaryl-8-azabicyclo[3,2,1]octanes as antipsychotic agents, 5-HT3 receptor antagonists and inhibitors of the reuptake of serotonin | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-02 | — | — | US | disclosed |
| US-5234931-A | Anxiolytic agents; antdepressants; schizophrenia; drug abuse; medical diagnosis | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0498331-A1 | N-(aryloxyalkyl)heteroaryl-8-azabicyclo(3.2.1)octanes, intermediates and a process for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | CA12 4862/4885CA1 4355/4885CA2 4569/4885 |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | CA12 4862/4885CA1 4355/4885CA2 4569/4885 |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | CA12 4862/4885CA1 4355/4885CA2 4569/4885 |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | CA12 4862/4885CA1 4355/4885CA2 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.